Chromosome translocations in multiple myeloma
The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM), a malignant tumor of somatically mutated, isotype-switched plasma cells (PC), usually arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS). MM progresses within the bone marrow, and then to an extramedullary stage from which MM cell lines are generated. The incidence of IgH translocations increases with the stage of disease: 50% in MGUS, 60-65% in intramedullarly MM, 70-80% in extramedullary MM, and >90% in MM cell lines. Primary, simple reciprocal IgH translocations, which are present in both MGUS and MM, involve many partners and provide an early immortalizing event. Four chromosomal partners appear to account for the majority of primary IgH translocations: 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), and 16q23 (c-maf). They are mediated primarily by errors in IgH switch recombination and less often by errors in somatic hypermutation, with the former dissociating the intronic and 3' enhancer(s), so that potential oncogenes can be dysregulated on each derivative chromosome (e.g., FGFR3 on der14 and MMSET on der4). Secondary translocations, which sometimes do not involve Ig loci, are more complex, and are not mediated by errors in B cell specific DNA modification mechanisms. They involve other chromosomal partners, notably 8q24 (c-myc), and are associated with tumor progression. Consistent with MM being the malignant counterpart of a long-lived PC, oncogenes dysregulated by primary IgH translocations in MM do not appear to confer an anti-apoptotic effect, but instead increase proliferation and/or inhibit differentiation. The fact that so many different primary transforming events give rise to tumors with the same phenotype suggests that there is only a single fate available for the transformed cell.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 40% of multiple myeloma is characterized by the presence of trisomies in the neoplastic plasma cells (hyperdiploid multiple myeloma), while most of the rest have a translocation involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 (IgH translocated multiple myeloma).38–41”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [39]
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,774
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Cancer: Principles and Practice of Oncology.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-506_5 · Cited by 1,900
Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7824 · Cited by 1,773
Anderson, P. C. (1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.281.24.2351 · Cited by 1,006
Cellular Origin of Human B-Cell Lymphomas
Küppers, R., Klein, U., Hansmann, M.-L., & Rajewsky, K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911113412007 · Cited by 715
The Proto-Oncogene c-maf Is Responsible for Tissue-Specific Expression of Interleukin-4
Ho, I.-C., Hodge, M. R., Rooney, J. W., & Glimcher, L. H. (1996) · Cell · doi:10.1016/s0092-8674(00)81299-4 · Cited by 667
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637 · cited 2×
“…of conventional cytogenetics, SKY analyses, metaphase FISH analyses, isolation of molecular clones, and RT±PCR assays (Bergsagel et al., 1996; Chesi et al., 1997, 1998a; Gabrea et al., 1999; Shaughnessy et al., 2001; Shou et al., 2000; Kuehl, 2001, unpublished results), we have identi®ed at…”
BackgroundSelf-citationChesi, M., Nardini, E., Lim, R. S. C., Smith, K. D., Kuehl, W. M., & Bergsagel, P. L. (1998) · Blood · doi:10.1182/blood.v92.9.3025 · Cited by 572
Self-citationDNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation
Difilippantonio, M. J., Zhu, J., Chen, H. T., Meffre, E., Nussenzweig, M. C., Max, E. E., Ried, T., & Nussenzweig, A. (2000) · Nature · doi:10.1038/35006670 · Cited by 547
Research works printed but not linked: 1
- Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK . 2000 SEER Cancer Statistics Review, 1973–1997 National Cancer Institute: Bethesda
Cited by
Items 201–300 of 545
Mechanisms of Resistance in Multiple Myeloma
Papadas, A., & Asimakopoulos, F. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_10 · Cited by 30
Multistep Tumorigenesis of Multiple Myeloma: Its Molecular Delineation
Iida, S., & Ueda, R. (2003) · International Journal of Hematology · doi:10.1007/bf02983776 · Cited by 30
New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway
van de Donk, N. W. C. J., Bloem, A. C., van der Spek, E., & Lokhorst, H. M. (2005) · Current Pharmaceutical Design · doi:10.2174/138161206775201974 · Cited by 30
Khuda, S. E., Loo, W. M., Janz, S., Ness, B. G. V., & Erickson, L. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.7537 · Cited by 30
Tumour‐associated antigens in multiple myeloma
Pellat‐Deceunynck, C. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.03760.x · Cited by 30
The mechanisms of vitamin K2-induced apoptosis of myeloma cells.
Tsujioka, T., Miura, Y., Otsuki, T., Nishimura, Y., Hyodoh, F., Wada, H., & Sugihara, T. (2006) · PubMed · Cited by 29
Establishment and exploitation of hyperdiploid and non‐hyperdiploid human myeloma cell lines
Li, X., Pennisi, A., Zhan, F., Sawyer, J. R., Shaughnessy, J. D., & Yaccoby, S. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06742.x · Cited by 29
Gene expression profiling and multiple myeloma
Shaughnessy, J. D., Zhan, F., Barlogie, B., & Stewart, A. K. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.02.003 · Cited by 30
Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
Alzrigat, M., Jernberg‐Wiklund, H., & Licht, J. D. (2018) · Epigenomes · doi:10.3390/epigenomes2030016 · Cited by 28
Micallef, J., Dharsee, M., Chen, J., Ackloo, S. Z., Evans, K., Qiu, L., & Chang, H. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-13 · Cited by 28
Cancer stem cells and the cellular hierarchy in haematological malignancies
Johnsen, H. E., Kjeldsen, M. K., Urup, T. H., Fogd, K., Pilgaard, L., Boegsted, M., Nyegaard, M., Christiansen, I., Bukh, A., & Dybkær, K. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70033-4 · Cited by 29
Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma
Yeung, J. C., & Chang, H. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.049585 · Cited by 27
Chong, P. S. Y., Chooi, J.-Y., Lim, J. S. L., Toh, S. H. M., Tan, T. Z., & Chng, W. J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2946 · Cited by 26
Guikema, J. E. J., de Boer, C., Haralambieva, E., Smit, L. A., van Noesel, C. J. M., Schuuring, E. M. D., & Kluin, P. M. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20345 · Cited by 26
Takahashi, S. (2021) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.21-0027 · Cited by 25
Johnsen, H. E., Bergkvist, K. S., Schmitz, A., Kjeldsen, M. K., Hansen, S. M., Gaihede, M. L., Nørgaard, M. A., Bæch, J., Grønholdt, M.-L. M., Jensen, F. S., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.839785 · Cited by 26
Tian, E., Sawyer, J. R., Heuck, C. J., Zhang, Q., van Rhee, F., Barlogie, B., & Epstein, J. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22165 · Cited by 25
MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia
Pajcini, K. V., Xu, L., Shao, L., Petrovic, J., Palasiewicz, K., Ohtani, Y., Bailis, W., Lee, C., Wertheim, G. B. W., Mani, R., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aam6846 · Cited by 25
Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma
Soliman, A. M., Teoh, S. L., Mahakkanukrauh, P., & Das, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207539 · Cited by 26
Risk stratification in multiple myeloma, part 1: characterization of high-risk disease.
Biran, N., Jagannath, S., & Chari, A. (2013) · PubMed · Cited by 26
Cowan, G. J. M., Weston-Bell, N. J., Bryant, D. J., Seckinger, A., Hose, D., Zojer, N., & Sahota, S. S. (2015) · Oncotarget · doi:10.18632/oncotarget.3644 · Cited by 25
Class switch recombination: A friend and a foe
Edry, E., & Melamed, D. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.02.008 · Cited by 24
Yan, Y. L., Park, S. S., Janz, S., & Eckhardt, L. A. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20480 · Cited by 24
Molecular and transcriptional characterization of the novel 17p11.2‐p12 amplicon in multiple myeloma
Fabris, S., Todoerti, K., Mosca, L., Agnelli, L., Intini, D., Lionetti, M., Guerneri, S., Lambertenghi‐Deliliers, G., Bertoni, F., & Neri, A. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20494 · Cited by 23
Liu, Y., Miyazawa, K., Sashida, G., Kodama, A., & Ohyashiki, K. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.03.013 · Cited by 23
Cytogenetic manifestations of multiple myeloma heterogeneity
Pantou, D., Rizou, H., Tsarouha, H., Pouli, A. G., Papanastasiou, K., Stamatellou, M., Trangas, T. T., Pandis, N., & Bardi, G. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20114 · Cited by 23
Hodge, D. R., Xiao, W., Wang, L. H., Li, D., & Farrar, W. L. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.2.621 · Cited by 22
Fenton, J. A. L., Pratt, G., Rawstron, A. C., Sibley, K., Rothwell, D. G., Yates, Z. R., Dring, A. M., Richards, S. J., Ashcroft, A. J., Davies, F. E., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206335 · Cited by 22
Stella, F., Pedrazzini, E., Agazzoni, M., Ballester, O., & Slavutsky, I. R. (2015) · Cancer Investigation · doi:10.3109/07357907.2015.1080833 · Cited by 21
Thakral, D., Das, N., Basnal, A., & Gupta, R. (2020) · PubMed · Cited by 21
Structure and Consequences of IGH Switch Breakpoints in Burkitt Lymphoma
Guikema, J. E. J., Schuuring, E. M. D., & Kluin, P. M. (2008) · JNCI Monographs · doi:10.1093/jncimonographs/lgn020 · Cited by 21
Damgaard, T., Knudsen, L. M., Dahl, I. M. S., Gimsing, P., Lodahl, M., & Rasmussen, T. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802699332 · Cited by 21
Ram, M., Fraser, M., Santos, J. V. D., Tasakis, R. N., Islam, A., Abo-Donia, J. U., Parekh, S. S., & Laganà, A. (2024) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s350238 · Cited by 20
Gastelum, G., Veena, M. S., Lyons, K., Lamb, C. J., Jacobs, N. M., Yamada, A., Baibussinov, A., Sarafyan, M., Shamis, R., Kraut, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703878 · Cited by 20
WWOX, large common fragile site genes, and cancer
Gao, G., & Smith, D. I. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370214565992 · Cited by 20
Review of molecular diagnostics in multiple myeloma
Stewart, A. K., & Fonseca, R. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.4.453 · Cited by 20
El-Ghammaz, A. M. S., & Abdelwahed, E. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2692-0 · Cited by 20
Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus
(2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0792-2.50018-3 · Cited by 20
Fiancette, R., Rouaud, P., Vincent‐Fabert, C., Laffleur, B., Magnone, V., Cogné, M., & Denizot, Y. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102059 · Cited by 19
Epigenetic silencing of EVL/miR-342 in multiple myeloma
Li, Z., Wong, K. Y., Chan, G., Chng, W. J., & Chim, C. S. (2017) · Translational research · doi:10.1016/j.trsl.2017.11.005 · Cited by 19
Correlates of imexon sensitivity in human multiple myeloma cell lines
Samulitis, B. K., Landowski, T. H., & Dorr, R. T. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500266210 · Cited by 19
The RB protein: more than a sentry of cell cycle entry
Thangavelu, P. U., Lin, C., Forouz, F., Tanaka, K., Dray, E. V., & Duijf, P. H. G. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.04.001 · Cited by 18
Xu, Y., Sun, T., Zeng, K., Xu, M., Chen, J., Xu, X., Zhang, Z., Cao, B., Tang, X., Wu, D., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03017-4 · Cited by 18
Fenton, J. A. L., Pratt, G., Rothwell, D. G., Rawstron, A. C., & Morgan, G. J. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10304 · Cited by 18
The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”
Solimando, A. G., Vià, M. D., Bolli, N., & Steinbrunn, T. (2022) · Cancers · doi:10.3390/cancers14133271 · Cited by 17
Boulos, J. C., Chatterjee, M., Shan, L., & Efferth, T. (2023) · Cancers · doi:10.3390/cancers15164136 · Cited by 16
Grigoriadis, G., Gilbertson, M., Came, N. A., Westerman, D., Feleppa, F., Jene, N., Chapple, P., & Juneja, S. (2012) · Pathology · doi:10.1097/pat.0b013e3283583f5d · Cited by 16
Bong, I. P. N., Ching, N. C., Meng, C. K., & Zakaria, Z. (2012) · Hematology Reports · doi:10.4081/hr.2012.e19 · Cited by 16
An update on molecular biology and drug resistance mechanisms of multiple myeloma
Mutlu, P., Kiraz, Y., Gündüz, U., & Baran, Y. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.07.003 · Cited by 17
IgD myeloma indicated by plasma cells in the peripheral blood and massive pleural effusion
Natori, K., Izumi, H., Nagase, D., Fujimoto, Y., Ishihara, S., Kato, M., Umeda, M., & Kuraishi, Y. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0444-5 · Cited by 16
Pozdnyakova, O., Morgan, E. A., Li, B., Shahsafaei, A., & Dorfman, D. M. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.676174 · Cited by 16
Gutierrez, N. C., García‐Sánz, R., & Miguel, J. F. S. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0114-4 · Cited by 17
Sun, J., Senitzer, D., Forman, S. J., Chatterjee, S., & Wong, K. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0415-6 · Cited by 16
Hematological malignancies: myeloma
Dimopoulos, M. A., Kastritis, E., & Anagnostopoulos, Α. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl251 · Cited by 16
Mao, X., Zhuang, J., Zhao, D., Li, X., Du, X., Hao, M., Xu, Y., Yan, Y., Liu, J., Fan, H., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13440 · Cited by 15
Kiyota, M., Kobayashi, T., Fuchida, S., Yamamoto‐Sugitani, M., Ohshiro, M., Shimura, Y., Mizutani, S., Nagoshi, H., Sasaki, N., Nakayama, R., et al. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1035-8 · Cited by 15
Standardisation of minimal residual disease in multiple myeloma
Innao, V., Allegra, A., Russo, S., Gerace, D. G., Vaddinelli, D., Alonci, A., Allegra, A. G., & Musolino, C. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12732 · Cited by 15
Enhancing B-Cell Malignancies—On Repurposing Enhancer Activity towards Cancer
Kasprzyk, M. E., Sura, W., & Dzikiewicz‐Krawczyk, A. (2021) · Cancers · doi:10.3390/cancers13133270 · Cited by 15
Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma
Ahmed, M. I., Giles, F. J., Joe, Y., Weber, D. M., Jilani, I. B., Manshouri, T., Giralt, S., Lima, M. J. G. D., Keating, M. J., & Albitar, M. X. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.00125.x · Cited by 15
MYC alterations in multiple myeloma: Genetic insights and prognostic impact
Cristobal‐Vargas, S., Cuadrado, M., & Gutierrez, N. C. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101177 · Cited by 14
Jung, H. A., Jang, M., Kım, K., & Kim, S. (2018) · Annals of Laboratory Medicine · doi:10.3343/alm.2018.38.3.196 · Cited by 14
Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells
Ramakrishnan, V., & Mager, D. E. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.247924 · Cited by 14
Genomic profiling of multiple myeloma: New insights and modern technologies
Hultcrantz, M. L., Yellapantula, V. D., & Rustad, E. H. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101153 · Cited by 15
Khalili, P., Maddah, R., Maleknia, M., Amiri, B. S., Forouzani, F., Hasanvand, A., & Rezaeeyan, H. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00634-6 · Cited by 14
Chromosomal and genetic abnormalities in myeloma
Ho, P. J. (2002) · Clinical & Laboratory Haematology · doi:10.1046/j.1365-2257.2002.00456.x · Cited by 14
Qian, S., Somlo, G., Zhou, B., Zhu, L., Mi, S., Mo, X., Cheung, E. M., Qiu, W., Lin, R.-J., Rossi, J. J., et al. (2005) · Oligonucleotides · doi:10.1089/oli.2005.15.1 · Cited by 14
Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH
Boersma‐Vreugdenhil, G. R., Peeters, T., Bast, B. J. E. G., & Lokhorst, H. M. (2003) · Blood · doi:10.1182/blood-2002-09-2968 · Cited by 14
Tonon, G. (2023) · Blood · doi:10.1182/blood.2023021384 · Cited by 13
Longo, L. V. G., Hughes, T. L., McNeil-Laidley, B., Cottini, F., Hilinski, G., Merritt, E., & Benson, D. M. (2023) · Haematologica · doi:10.3324/haematol.2023.282838 · Cited by 13
Türkmen, S., Binder, A., Gerlach, A., Niehage, S., Melissari, M., İnandıklıoğlu, N., Dörken, B., & Burmeister, T. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22175 · Cited by 13
Oncology: Treatment of Multiple Myeloma in the Targeted Therapy Era
Saad, A. A., Sharma, M. R., & Higa, G. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l428 · Cited by 13
Dolloff, N. G., Allen, J. E., Dicker, D. T., Aqui, N. A., Vogl, D. T., Malysz, J., Talamo, G., & El‐Deiry, W. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0578 · Cited by 13
Kelley, T. W., Baz, R., Hussein, M. A., Karafa, M., & Cook, J. R. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.09.006 · Cited by 13
Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma
Shi, Y., Sun, F., Cheng, Y., Holmes, B., Dhakal, B., Gera, J., Janz, S., & Lichtenstein, A. K. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0016 · Cited by 12
Multiple Myeloma: Current Perspectives
Slovak, M. L. (2011) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2011.08.009 · Cited by 12
t(11;14) does not predict long-term survival in myeloma
Chang, H., Qi, X., & Stewart, A. K. (2005) · Leukemia · doi:10.1038/sj.leu.2403744 · Cited by 12
Heterogeneity in the Multiple Myeloma Tumor Clone
Guikema, J. E. J., Hovenga, S., Vellenga, E., & Bos, N. A. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190310001593201 · Cited by 13
Guikema, J. E. J., Fenton, J. A. L., de Boer, C., Kleiverda, K., Brink, A. A. T. P., Raap, A. K., Estrov, Z. E., Schuuring, E. M. D., & Kluin, P. M. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20132 · Cited by 12
Li, S., Liu, J., Peyton, M., Lazaro, O., McCabe, S., Huang, X., Liu, Y., Shi, Z., Zhang, Z., Walker, B. A., et al. (2025) · Cancers · doi:10.3390/cancers17040653 · Cited by 11
Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma
Sharma, N., & Choudhary, B. (2023) · Biomolecules · doi:10.3390/biom13111629 · Cited by 11
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
Wong, K. Y., Wan, T. S., So, C. C., & Chim, C. S. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-122 · Cited by 11
MafB, a target of microRNA-155, regulates dendritic cell maturation
Yang, L., Li, R., Xiang, S., & Xiao, W. (2016) · Open Life Sciences · doi:10.1515/biol-2016-0006 · Cited by 11
Demchenko, Y. N., Roschke, A. V., Chen, W.-D. D., Asmann, Y. W., Bergsagel, P. L., & Kuehl, W. M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw527 · Cited by 11
Self-citationNdacayisaba, L. J., Rappard, K. E., Shishido, S. N., Velasco, C. R., Matsumoto, N., Navarez, R., Tang, G., Lin, P., Setayesh, S. M., Naghdloo, A., et al. (2022) · Current Oncology · doi:10.3390/curroncol29050242 · Cited by 11
The Role of DNA Repair in Genomic Instability of Multiple Myeloma
Ali, J. Y. H., Fitieh, A. M., & Ismail, I. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105688 · Cited by 11
HDAC1 promotes the migration of human myeloma cells via regulation of the lncRNA/Slug axis
Zheng, L., Zhang, A., Liu, J., Liu, M., & Zhang, Y. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.5058 · Cited by 11
Hu, Y., Zheng, M., Gali, R. R., Tian, Z., Görgün, G., Munshi, N. C., Mitsiades, C. S., & Anderson, K. C. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.53 · Cited by 11
Genomics in Multiple Myeloma: Biology and Clinical Implications
Chng, W. J., & Fonseca, R. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.6.563 · Cited by 11
Qi, C., Shin, D., Li, Z., Wang, H., Feng, J., Hartley, J. W., Fredrickson, T. N., Kovalchuk, A. L., & Morse, H. C. (2010) · The Journal of Pathology · doi:10.1002/path.2692 · Cited by 11
Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier
Grasedieck, S., Panahi, A., Jarvis, M. C., Borzooee, F., Harris, R. S., Larijani, M., Avet‐Loiseau, H., Samur, M., Munshi, N. C., Song, K., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02210-0 · Cited by 10
Discovery platform for inhibitors of IgH gene enhancer activity
Dolloff, N. G. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1538615 · Cited by 10
Kim, G. Y., Gabrea, A., Demchenko, Y. N., Bergsagel, P. L., Roschke, A. V., & Kuehl, W. M. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22158 · Cited by 10
Self-citationSantra, M., Shaughnessy, J., & Bellamy, W. T. (2010) · Biotechnic & Histochemistry · doi:10.3109/10520290903565978 · Cited by 10
Utilizing BMP-2 muteins for treatment of multiple myeloma
Seher, A., Lagler, C., Stühmer, T., Müller-Richter, U. D. A., Kübler, A. C., Sebald, W., Müller, T. D., & Nickel, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174884 · Cited by 10
Shetty, S., Siady, M., Mallempati, K. C., Wilson, A. R., Poarch, J., Chandler, B., Gray, J., & Salama, M. E. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1021-1 · Cited by 10
Krieger, S., Grunau, C., Sabbah, M., & Sola, B. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.03.011 · Cited by 10
Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia
Miura, K., Lida, S., Hanamura, I., Kato, M., Banno, S., Ishida, T., Kusumoto, S., Takeuchi, G., Miwa, H., Nitta, M., et al. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01445.x · Cited by 10
Chiriva‐Internati, M., Cobos, E., & Kast, W. M. (2007) · International Reviews of Immunology · doi:10.1080/08830180701365966 · Cited by 10
Ilić, V. L., Milosević-Jovčić, N., Marković, D. C., Petrovic, S., & Stefanović, G. (2007) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.2007.00673.x · Cited by 9
Bødker, J. S., Brøndum, R. F., Schmitz, A., Schönherz, A. A., Jespersen, D. S., Sønderkær, M., Vesteghem, C., Due, H., Nørgaard, C. H., Pérez‐Andrés, M., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018018564 · Cited by 9
Metadata
- Authors
- Bergsagel, P. L., & Kuehl, W. M.
- Affiliations
- Cornell University (US)
- National Cancer Institute (US)
- Corresponding author
- Bergsagel, P Leif
- ORCID
- Bergsagel, P Leif
- Venue
- Oncogene
- Published
- 2001-09-10
- Volume
- 20
- Issue
- 40
- Pages
- 5611-5622
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1977707370
- Cited by
- 478
- References
- 64
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 16 · 2022: 17 · 2021: 16 · 2020: 13 · 2019: 12 · 2018: 11 · 2017: 15 · 2016: 17 · 2015: 21 · 2014: 16 · 2013: 26 · 2012: 19
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- multiple myeloma, chromosomal translocation, immunoglobulin heavy chain locus, monoclonal gammopathy of undetermined significance, cyclin D1, cyclin D3, FGFR3, MMSET, c-Maf, c-Myc, somatic hypermutation, tumor progression, extramedullary myeloma
- MeSH terms
- Cell Line, Transformed, Chromosomes, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 16, Chromosomes, Human, Pair 4, Chromosomes, Human, Pair 6, Chromosomes, Human, Pair 8, Humans, Immunoglobulins, Models, Genetic, Multiple Myeloma, Phenotype, Translocation, Genetic, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.